Supplements

CGM-guided dietary titration improves Time in Range in hepatic GSD patients

In interventional settings, CGM-guided dietary titration improved Time in Range from 72% to 86% in gene therapy trials, and reduced serum triglycerides and liver size. CGM consistently identified asymptomatic hypoglycemia, with adult cohorts spending up to 12% of time below range despite normal spot checks.

Last updated: Jul 8, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes.

observational

Mohsenipour R, Abbasi F, Ghaderian MS, Dehkordi AK, Abdolahpour S, Akbari K · Endocrinology, diabetes & metabolism (2026)

Participants: N/A
Duration: N/A
Intervention: CGM-guided dietary titration
Outcome: Time in Range (TIR), serum triglycerides, liver size
Effect Size: N/A
Population: Patients with hepatic Glycogen Storage Diseases (GSD), predominantly GSD Ia, Ib and III

Result:

PubMed: 42394382DOI: 10.1002/edm2.70274

Mechanism Graph

CGM detects asymptomatic hypoglycemic excursions missed by intermittent monitoring
↓
Data guides dietary adjustments to stabilize glucose levels
↓
Improved glucose control reduces metabolic abnormalities (triglycerides, liver size)
↓
Result: Increased Time in Range and improved clinical outcomes

Limitations

  • ⚠Sensor performance showed a positive bias in the hypoglycemic range, potentially masking severe neuroglycopenia
  • ⚠CGM introduced 'alarm fatigue' from false-positive alerts, impacting patient burden

Frequently Asked Questions

What is the main benefit of CGM in GSD patients?▼

CGM offers superior sensitivity for detecting occult hypoglycemia and guiding therapy, shifting management from reactive treatment to proactive stabilization.

How much did Time in Range improve with CGM-guided titration?▼

In gene therapy trials, Time in Range improved from 72% to 86%.

What are the limitations of CGM in GSD?▼

Sensor inaccuracy at lower glucose levels can mask severe neuroglycopenia, and false-positive alerts cause alarm fatigue.

Which GSD subtypes were studied?▼

The review predominantly included GSD Ia, Ib and III.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Mohsenipour R, Abbasi F, Ghaderian MS, Dehkordi AK, Abdolahpour S, Akbari K. "Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes.." Endocrinology, diabetes & metabolism, 2026. PMID: 42394382 DOI: 10.1002/edm2.70274
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.